Skip to main content
Healthcare professionals talking to their patients in clinical practice

We Are Working to Improve Cardiovascular Health

Amarin’s Innovation in Cardiovascular Disease (CVD) Management

Working together to advance pathways in cardiovascular risk management

Cardiovascular disease management requires commitment and innovation. Despite optimal management of risk factors such as low-density lipoprotein cholesterol (LDL-C), many patients remain at risk of cardiovascular events.1 To reduce the burden of CVD, emerging therapeutic modalities should be explored to address drivers of residual risk.1

To provide effective cardiovascular prevention, it is crucial to share information on the evolving CVD landscape and discuss central questions in CVD management.

How can we fight cardiovascular disease today?

Grey background
A male doctor at his desk looks at a monitor 

Facing the challenges of CVD today

Read more about the impact and the burden of CVD, therapeutic options and persistent risk beyond LDL-C lowering.2 

 Experienced doctor with an elderly female patient

Amarin in the UK

Cardiovascular disease is a persistent and growing health burden. Our ambition in the UK is to be part of the solution in addressing this important health issue.

Male employee shaking hands meeting the team


Your future is our future so if you are looking for a new opportunity, join Amarin. Together we can achieve great things and improve patients’ lives.

Female doctor smiling with female and male patients


We’ve got some exciting plans in the UK. Explore our latest news and stay up to date with the innovative work we’re doing.

Pharmacy cross

Our Products

A female HCP performing a consultation by phone



Tel: 0800 0478673
E-Mail: [email protected]

  1. Dhindsa DS, Sandesara PB, Shapiro MD, Wong ND. The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. Front Cardiovasc Med. 2020;7:88.
  2. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37:2999-3058.

Clinical Trials

We continue to share clinical trial results of all sponsored Phase I, Phase II, Phase III and Phase IV clinical trials of Amarin marketed products conducted anywhere in the world on Amarin also seeks to publish study results through peer-reviewed journals and scientific conferences.

This website is intended for residents of the UK only. It is available to the general public for informational purposes only and should not be used for diagnosis or treatment of a health problem or disease. It is not intended as a substitute for consultation with a healthcare provider. Please consult your healthcare provider for further advice.